
EIGR
Healthcare · Biotechnology · $2.6M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · -159.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 8, 2024 | After the close | -7.50 | -49.39 | -558.5% |
| Mar 27, 2024 | After the close | -7.50 | -9.09 | -21.2% |
| Nov 9, 2023 | After the close | -0.32 | -0.41 | -28.1% |
| Aug 14, 2023 | After the close | -0.41 | -0.47 | -14.6% |
| May 11, 2023 | After the close | -0.47 | -0.52 | -10.6% |
| Mar 16, 2023 | After the close | -0.54 | -0.57 | -5.6% |
| Nov 3, 2022 | After the close | -0.52 | -0.62 | -19.2% |
| Aug 4, 2022 | After the close | -0.61 | -0.51 | +16.4% |
| May 5, 2022 | After the close | -0.64 | -0.64 | 0.0% |
| Mar 10, 2022 | After the close | -0.64 | -0.64 | 0.0% |
| Nov 4, 2021 | After the close | -0.56 | -0.65 | -16.1% |
| Aug 5, 2021 | After the close | -0.55 | -0.57 | -3.6% |
| May 6, 2021 | After the close | -0.02 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate…
| -0.51 |
| -2450.0% |
| Mar 9, 2021 | After the close | 0.25 | -0.57 | -328.0% |
| Nov 5, 2020 | After the close | -0.59 | -0.52 | +11.9% |
| Aug 6, 2020 | After the close | -0.71 | -0.60 | +15.5% |
| May 7, 2020 | After the close | -0.80 | -0.62 | +22.5% |
| Mar 13, 2020 | Before the open | -0.43 | -0.68 | -58.1% |
| Nov 7, 2019 | After the close | -0.75 | -0.76 | -1.3% |
| Aug 8, 2019 | After the close | -0.74 | -0.75 | -1.4% |
| May 9, 2019 | After the close | -0.95 | -0.90 | +5.3% |
| Mar 14, 2019 | After the close | -0.82 | -0.92 | -12.2% |
| Nov 9, 2018 | Before the open | -0.74 | -1.20 | -62.2% |
| Aug 10, 2018 | Before the open | -0.82 | -0.82 | 0.0% |
| May 11, 2018 | Before the open | -1.04 | -0.84 | +19.2% |
| Mar 9, 2018 | After the close | -1.02 | -1.09 | -6.9% |